In this first of two podcasts, Dr. Rana R. McKay discusses the optimal treatment selection and management of adverse events for patients with metastatic and nonmetastatic castration-sensitive prostate cancer (CRPC), including the use of taxanes, androgen receptor agonists, and other therapies.

This activity is available for CE/CME credit. Claim your credit at pce.is/GIGU.

Contributors:

Arjun Balar, MD

Rana R. McKay, MD

Terran W. Sims, MSN, ACNP-C, CNN-BC, COCN

Dr Balar: consulting fees: Bristol-Myers Squibb, Incyte, Istari Oncology, Janssen, Pfizer; consulting fees/research support: Immunomedics, Seagen; consulting fees/contracted research/fees for non-CME/CE services: AstraZeneca/Medimmune, Genentech; Merck; consulting fees/contracted research: Immunomedics/Gilead, Nektar, Seagen; consulting/ownership interest: EpiVax Oncology, GT Biopharma.

Dr McKay: consulting fees: AstraZeneca, Bristol-Myers Squibb, Calithera, Caris, Dendreon, Exelixis, Janssen, Merck, Myovant, Novarits, Sanofi, Sorrento Therapeutics; Vividion Therapeutics; consulting fees/contracted research: Bayer, Pfizer, Tempus.

Ms Sims: consulting fees: Coloplast.